Publications by authors named "Qinyi Su"
Autoimmune diseases are characterized by the body's immune system attacking its own cells, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). In recent studies, regulatory B cells (Bregs), which play a vital role in maintaining peripheral tolerance and controlling persistent autoimmune diseases (ADs), have shown great potential in treating ADs. This review synthesizes the latest advancements in targeted therapies for ADs, with a particular emphasis on the subgroups, phenotypic markers, and signal pathways associated with Bregs.
View Article and Find Full Text PDFBackground: Ankylosing spondylitis (AS) is a connective tissue disease that primarily affects spinal joints, peripheral joints, and paravertebral soft tissues, leading to joint stiffness and spinal deformity. Growing evidence has implicated gut microbiota in the regulation of AS, though the underlying mechanisms remain poorly understood.
Methods: We conducted a comprehensive search of PubMed, Embase, Web of Science, the Cochrane Library, MEDLINE, Wanfang Data, China Science and Technology Journal Database (VIP), and China National Knowledge Internet (CNKI) databases from the time the databases were created until 30 July 2023.
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target.
Expert Opin Biol Ther
October 2024
Introduction: Psoriatic arthritis (PsA) is a debilitating chronic condition characterized by inflammation of the joints, bones, enthesis, and skin. The pivotal role of interleukin-23 (IL-23) in the pathogenesis of PsA has become increasingly evident. This proinflammatory cytokine is markedly elevated in patients with PsA, suggesting its potential as a therapeutic target.
View Article and Find Full Text PDFArticle Synopsis
- Difficult-to-treat Rheumatoid arthritis (D2T RA) is defined by the lack of response to at least two different biologic drugs, leading to ongoing disease activity, prompting a systematic review of treatment options.
- The study reviewed 42 randomized controlled trials to evaluate the effectiveness and safety of various drugs, finding that tocilizumab, baricitinib, and olokizumab ranked highest in improving disease activity scores.
- The results suggest that tocilizumab, particularly at an 8 mg/4-week dosage, alongside rituximab, are effective and safe options for managing D2T RA, marking tocilizumab as a leading choice for treatment.
Background: Immunotherapy targeting factors related to immune imbalance has been widely employed for RA treatment. This study aimed to evaluate the efficacy and safety of low-dose interleukin (IL)-2 combined with tocilizumab (TCZ), a biologics targeting IL-6, in RA patients.
Methods: Fifty adults with active RA who met the criteria with complete clinical data were recruited, and divided into three groups: control group (n=15), IL-2 group (n=26), and IL-2+TCZ group (n=9).
Article Synopsis
- - Bimekizumab is a monoclonal antibody that targets interleukin-17A and IL-17F, showing promise in treating Psoriatic arthritis (PsA).
- - A systematic review of 4 randomized controlled trials (RCTs) with 892 PsA patients found that bimekizumab significantly improved skin and joint symptoms compared to placebos, although there was a slight increase in overall adverse events.
- - The study concluded that bimekizumab offers meaningful clinical benefits for PsA management while maintaining an acceptable safety profile.
Rheumatoid arthritis (RA) is a complex autoimmune inflammatory rheumatic disease characterized by an imbalance between immunological reactivity and immune tolerance. Regulatory T cells (Tregs), which play a crucial role in controlling ongoing autoimmunity and maintaining peripheral tolerance, have shown great potential for the treatment of autoimmune inflammatory rheumatic diseases such as RA. This review aims to provide an updated summary of the latest insights into Treg-targeting techniques in RA.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the causal relationship between nine lifestyle factors and erectile dysfunction (ED) using advanced genetic analysis methods.
- Findings suggested that smoking, alcohol consumption, and higher body mass index (BMI) are associated with increased ED risk, while an earlier age at first intercourse may reduce that risk.
- Overall, the study aimed to clarify the impact of these lifestyle factors on ED, highlighting some areas where lifestyle changes might be beneficial but found no strong evidence for certain factors like coffee intake or physical activity.
Article Synopsis
- Psoriatic arthritis (PsA) remains an unclear condition with limited treatment effectiveness, leading to the FDA's approval of risankizumab in 2019 as a therapeutic option targeting IL-23.
- A meta-analysis was conducted on six randomized controlled trials involving 5,038 patients, assessing the effectiveness and safety of risankizumab compared to a placebo over a 24-week period.
- Results demonstrated that patients receiving risankizumab achieved significantly better outcomes in terms of response rates (ACR20 and Minimal Disease Activity), improved overall health status (measured by SF-36), and reduced disability (HAQ-DI), indicating its potential benefit in managing moderate to severe PsA.
Introduction: Existing therapies of systemic lupus erythematosus (SLE) are efficacious only in certain patients. Developing new treatment methods is urgent. This meta-analysis aimed to evaluate the efficacy and safety of low-dose IL-2 (LD-IL-2).
View Article and Find Full Text PDFIntroduction: Current therapies for autoimmune rheumatic diseases (ARDs) have limited efficacy in certain patients, highlighting the need for the development of novel treatment approaches. This meta-analysis aims to assess the efficacy and safety of low-dose interleukin-2 (LD-IL-2) and evaluate the alterations in lymphocyte subsets in various rheumatic diseases following administration of different dosages of LD-IL-2.
Methods: A comprehensive search was conducted in PubMed, Web of Science, the Cochrane Library, Embase databases and CNKI to identify relevant studies.
Background: As one of the most critical proteins in the JAK/STAT signaling pathway, Janus kinase 2 (JAK2) is involved in many biological processes and diseases. Several observational studies have reported the role of JAK2 in erectile dysfunction. However, the causal relationship between JAK2 and erectile dysfunction remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- Regulatory T cells (Tregs) play a key role in immune tolerance, and their status is investigated in patients with refractory rheumatoid arthritis (RA), revealing an imbalance with decreased Tregs and increased Th17 cells.
- In a study with 41 RA patients and 40 healthy controls, low-dose interleukin-2 (IL-2) therapy was tested, showing it effectively increased CD4 Tregs and improved the Treg-Th17 balance.
- The findings suggest that the loss of Tregs correlates with disease activity in refractory RA, while low-dose IL-2 therapy may promote remission without significant side effects.
Introduction: Studies on the level of regulatory T (T) cells in psoriatic arthritis (PsA) have been controversial, leading to disagreement regarding the role T cells play in the pathogenesis of the disease. To clarify the status of T cells in patients with PsA, we performed a meta-analysis to determine the levels of T cells and serum T-associated cytokines in PsA patients.
Methods: According to published data from PubMed, Web of Science, Embase, Clinical Trials.
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease. Several proinflammatory cytokines produced by T helper 17 (Th17) cells are involved in the pathogenesis of AS. We performed a meta-analysis to determine the levels of Th17 cells and serum Th17-associated cytokines in patients with AS.
View Article and Find Full Text PDFThe best time window of percutaneous coronary intervention (PCI) is within 12 hours for ST-segment elevation myocardial infarction (STEMI). However, there is limited evidence about the proper time of PCI for delayed STEMI patients.From June 2014 to June 2015, a total of 268 patients receiving PCI with second-generation drug-eluting stent in a Chinese hospital after 3 days of STEMI onset were enrolled in this retrospective study, who were divided into the early group (3-14 days) and the late group (>14 days).
View Article and Find Full Text PDFViral myocarditis (VMC) commonly triggers heart failure, for which no specific treatments are available. This study aims to explore the specific role of long non-coding RNA (lncRNA) maternally expressed 3 (MEG3) in VMC. A VMC mouse model was induced by Coxsackievirus B3 (CVB3).
View Article and Find Full Text PDF